Chronic treatment with valium (diazepam) fails to affect the reproductive system of the male rat

Male rats treated chronically with high doses of Valium (50mg/ Kg/day; 10 days) failed to exhibit changes in their reproductive system. Testicular and prostate weights, serum testosterone (T) and LH were unaffected. Testes and pituitary tissue stimulated $\text{in}$$\text{vitro}$ with LH and GnRH, respectively, released normal amounts of T, LH and FSH. Brain benzodiazepine receptors were slightly but significantly elevated by Valium treatment as well as by castration. We conclude that the male reproductive system is resistant to chronic Valium treatment even though the brain levels of benzodiazepine receptors are not.     

Decreased Benzodiazepine Receptor Density in Rat Cerebellum Following Neurotoxic Doses of Phenytoin

Abstract: The effect of acute and chronic administration of phenytoin on [³H]-flunitrazepam binding was examined in the rat cerebellum. There was no significant effect of phenytoin on [³H]flunitrazepam binding in the rat cerebellum 1 and 6 h after a single i.p. injection of 200 mg/kg of phenytoin. However, after 14 days and 28 days of chronic phenytoin administration, significant de-creases in [³H]flunitrazepam receptor density were observed, with no changes in apparent affinity constants in the rat cerebellum. This effect of phenytoin was dose-dependent, as lower doses of phenytoin (100 mg/kg/day) for 14 or 28 days produced no alterations in [³H]flunitrazepam binding in the rat cerebellum. Light-microscopic examination of the rat cerebellum treated with 200 mg/kg/day of phenytoin for 14 days showed degeneration of the Purkinje cells, with edematous Bergmann astrocytes. These data provide evidence for the neuronal localization of benzodiazepine receptors on cerebellar Purkinje cells.     

Influence of prenatal d-amphetamine administration on development and behavior of rats.

Beginning on the fifth day of gestation, rats were administered 1 or 3 mg/kg of $\text{d}$-amphetamine sulfate s.c. twice daily until term. The administration of $\text{d}$-amphetamine caused a dose-related increase in pup mortality. However, the increase in pup death could not be correlated with any gross pathological signs. The surviving 3 mg/kg amphetamine pups were analyzed for changes in motor behavior and brain biogenic amine levels. It was found that the amphetamine offspring showed a marked reduction in the ability to habituate to new surroundings, and this effect persisted for at least three months after birth. On day 35, brain levels of norepinephrine in the “amphetamine” offspring were decreased 21 percent. On day 84, in the “amphetamine offspring,” norepinephrine levels were reduced 18 percent in both the diencephalon and brainstem; dopamine levels were reduced 21 percent in the brainstem compared to control offspring.     

LSD and related drugs as DA antagonists: Receptor-mediated effects on the synthesis and turnover of DA

We have earlier shown that d-lysergic acid diethylamide, LSD and its 2-bromo derivative, BOL like the dopamine (DA) antagonists haloperidol increased the rate of the $\text{in vivo}$ tyrosine hydroxylation in the striatum measured as the accumulation of DOPA after decarboxylase inhibition.Now we have found that several agents structurally similar to LSD increase the $\text{in vivo}$ tyrosine hydroxylation in the striatum. Psilocybin (50 mg/kg i.p.) and N,N-dimethyltryptamine (50 mg/kg i.p.) caused a short-lasting increase of DOPA accumulation, while mescaline (10 – 100 mg/kg i.p.) did not increase the DOPA accumulation. A marked increase of DOPA accumulation was observed after the 5-hydroxytryptamine (5-HT) antagonist cyproheptadine. The effects of LSD and structurally related drugs on the DOPA accumulation in the striatum appear to be mediated via DA antagonism at receptor level. However, these agents may control the DOPA accumulation via other receptors than DA receptors e.g. 5-HT receptors. A control of DOPA accumulation via receptors other than DA receptors appears to be predominant after treatment with N,N-dimethyltryptamine or psilocybin.     

Elevation of plasma tyrosine after a single oral dose of L-tyrosine.

Plasma tyrosine concentrations in twelve normal, fasting human subjects were significantly elevated 2–8 hours after they ingested 100 mg/kg or 150 mg/kg tyrosine. Mean plasma tyrosine levels were maximal after 2 hours, rising from $\text{69 ± 3.9}\text{to}\text{154 ± 9.5}\text{nmols/ml}\text{(}\text{X}\text{±}\text{SEM}\text{)}$ after the 100 mg/kg dose and to 203 ± 31.5 nmols/ml after the 150 mg/kg dose (p ≤ 0.001 for both doses). The mean tyrosine ratio (defined as the ratio of plasma tyrosine concentration to the sum of the concentrations of six other neutral amino acids that compete for the same blood-brain barrier uptake system) increased from $\text{0.10 ± 0.02}\text{to}\text{0.28 ± 0.04 (}\text{X}\text{±}\text{SEM}\text{)}$ 2 hours after the 100 mg/kg dose (p ≤ 0.001) and to 0.35 ± 0.05 2 hours after the 150 mg/kg dose (p ≤ 0.005). No side effects of orally-administered L-tyrosine were noted.     

Long-term amphetamine treatment attenuates or reverses the depression of neuronal activity produced by dopamine agonists in the ventral tegmental area

Neuronal activity was recorded from the ventral tegmental area (VTA) of immobilized, locally anesthetized rats on the day immediately following long-term treatment (twice daily for 6 consecutive days) with saline, 1.0 or 5.0 mg/kg $\text{d}$-amphetamine ($\text{d}$-AMPH). Each rat was challenged intravenously with $\text{d}$-AMPH (beginning with 0.0625 mg/kg) or with 0.005 mg/kg apomorphine. Treatment with $\text{d}$-AMPH significantly reduced the ability of this drug to inhibit VTA activity. In fact, nearly half of the neurons in the high-dose treatment group were excited by $\text{d}$-AMPH, whereas only 20% of control neurons showed this response. Moreover, apomorphine routinely accelerated firing rate in the VTA following treatment with 5.0 mg/kg $\text{d}$-AMPH but this response was never observed in control neurons, not even in those that were excited by $\text{d}$-AMPH. Thus, tolerance appears to develop to the ability of dopamine agonists to inhibit VTA activity and this effect may be mediated, at least in part, by a subsensitivity of inhibitory dopamine autoreceptors.     

Demonstration of [3H] diazepam binding to benzodiazepine receptors in vivo.

Benzodiazepine receptors were labeled with [³H] diazepam following intravenous injection in rats. Binding of [³H] diazepam $\text{in}$$\text{vivo}$ to rat forebrain membranes was displaceable by co-injection of clonazepam or the pharmacologically active enantiomers of two benzodiazepines, B9 and B10, but was not displaced by equal doses of the pharmacologically in-active enantiomers. Binding of [³H] diazepam $\text{in}$$\text{vivo}$ was bserved in kidney, liver, and abdominal muscle, but was not stereospecifically diplaced in any peripheral tissue studied. The regional distribution of benzodiazepine receptors in brain was uneven, with specific [³H] diazepam binding being highest in the cerebral cortex and lowest in the ponsmedulla. Preliminary studies of the subcellular distribution of [³H] diazepam binding demonstrated highest specific binding to synaptosomal membranes. These data demonstrate the feasibility of labeling benzodiazepine receptors in rat brain $\text{in}$$\text{vivo}$.     

The estrogenic activity of DDT: Correlation of estrogenic effect with nuclear level of estrogen receptor

Administration of o, p¹-DDT to immature female rats causes a translocation of estrogen receptors to uterine nuclei which is maximum 3 hours after pesticide treatment, and a subsequent increase in uterine weight at 24 hours. A high degree of correlation (r = 0.98) exists between the level of nuclear estrogen receptor and increases in uterine weight measured 3 and 24 hours respectively after administration of o, p¹-DDT, in the dose range of 10–1000 mg/kg. This high degree of correlation between these two parameters lends strong support to the hypothesis that the estrogenic effects observed following $\text{in vivo}$ administration of o, p¹-DDT result from the interaction of the pesticide with the classical estrogen receptor system.     

Precocious development in utero of certain UDP-glucuronyltransferase activities in rat fetuses exposed to glucocorticoids.

The first precocious development of UDP glucuronyltransferase in the mammalian fetus $\text{in utero}$ by a known compound of endogenous origin is described. Intraperitoneal injection of cortisol (8 mg) into maternal rats on days 14 and 15 of gestation stimulated fetal-liver transferase activity from near zero to $\text{1}\text{2}$ maternal levels by day 17; 0.3 mg dexamethasone, possessing a longer biological half-life, raised activity to full maternal level by day 16. In controls, injected with solvent only, fetal-liver transferase remained low on day 16. With both glucocorticoids, transferase stimulation was dose-dependent. Transferase activities were assayed in a range of digitonin concentrations from zero to above optimal for enzyme activation. Activities stimulated were towards $\text{o}$-aminophenol, $\text{p}$-nitrophenol, 1-naphthol and serotonin. Activities towards bilirubin, morphine and testosterone were not stimulated. The former group of activities are stimulated by glucocorticoids in culture and normally reach approximate adult levels just before birth; the latter group are not so stimulated on culture and normally reach adult levels after birth. Implications of these findings are discussed.     

Effects of morphine on cyclic AMP levels in the prostate glands of the mouse.

Morphine sulfate (20 mg/kg daily × 5 or 10 days) failed to produce any significant changes in the weights of the testes, liver or sex accessory organs. Injections of morphine for 1, 5 or 10 days caused significant increases in the prostate gland levels of ³H-cAMP (P < 0.01). Levels of ³H-cAMP formed from ³H-adenosine and endogenous cAMP were likewise observed to be elevated when prostate glands were incubated $\text{in vitro}$ with varying concentrations of morphine sulfate. When morphine sulfate (10, 20 or 40 mg/kg daily for 1, 5 or 10 days) was injected (s.c.), endogenous cyclic AMP levels were also significantly elevated in the prostate gland. The higher doses of morphine and the longer duration of its administration caused the greatest degree of elevation of endogenous cAMP. These dose regimens exerted little effect upon the liver's ability to metabolize tritiated testosterone.     

The effect of folate and folate analogs upon dihydrofolate reductase and DNA synthesis in kidneys of normal mice

A single subcutaneous injection of folate, homofolate or MTX resulted in the inhibition of the activity of dihydrofolate reductase in homogenates prepared from the kidneys of normal mice. Stimulation of ³H-thymidine uptake occurred in the kidneys of treated animals approximately 30 hr after administration of either folate or homofolate, and reached a peak 72 hr after administration. The effects of folate and MTX on dihydrofolate reductase activity $\text{in}$$\text{vivo}$ were also determined. One hr after administration of 15 mg/kg methotrexate (MTX) or 300 mg/kg folate, enzyme activity $\text{in}$$\text{vivo}$ was inhibited by 90%.³H-deoxyuridine uptake was neither stimulated nor depressed after treatment with MTX. After administration of folate, uptake of ³H-deoxyuridine was stimulated at approximately 30 hr after drug-treatment and reached a peak at 72 hr after folate administration. Treatment with xanthopterin had no effect on the activity of dihydrofolate reductase $\text{in}$$\text{vitro}$. Xanthopterin stimulated uptake of both deoxyuridine and thymidine in an identical manner.The increased DNA synthesis that occurs in animals after treatment with agents that cause renal damage is distinct from the effect these agents have upon dihydrofolate reductase. Nucleoside incorporation after treatment with folate, homofolate, MTX or xanthopterin cannot be predicted on the basis of enzyme inhibition. Treatment with MTX, folate or homofolate results in enzyme inhibition which is not correlated with the uptake of deoxyuridine into DNA.     

The effect of protein deficiency on the in vivo binding of aflatoxin B1 to rat liver macromolecules

Male, weanling rats divided into three groups were maintained for 15 days on a semipurified diet containing either 5% casein fed $\text{ad libitum}$ (group 1), 20% casein pair-fed to group 1 (group 2), or 20% casein fed $\text{ad libitum}$ (group 3). Animals on day 16 were injected i.p. with ³H-AFB₁ (1.90 mg/kg) and were sacrificed six hours later. In both the control and protein deficient animals, binding of AFB₁ to DNA was greater than that for chromatin protein. In the protein deficient animals, there was a consistent decrease (70%) in binding to chromatin, DNA and chromatin protein. The decrease in binding to nuclear macromolecules in protein deficient animals is correlated with carcinogenicity and mixed function oxidase (MFO) enzyme activity, and the relationships between carcinogenicity, MFO activity, and binding are discussed.     

The estrogenic activity of DDT: Invivo and invitro induction of a specific estrogen inducible uterine protein by o,p'-DDT

The pesticide o,p'-DDT stimulates the production of a specific uterine protein, the so-called induced protein or IP, normally associated with an estrogenic response of the uterus. $\text{In}$$\text{vivo}$ stimulation of IP production is observed 1 hour after the administration of 250 mg/kg of o,p'-DDT to immature rats. $\text{In}$$\text{vitro}$ stimulation of IP production is observed after a 1 hour incubation of uteri with 100 μM o,p'-DDT. This $\text{in}$$\text{vitro}$ response is blocked by Actinomycin D. In contrast to o,p'-DDT, which binds to the cytoplasmic estrogen receptor and stimulates IP production, p,p'-DDT which does not bind well to the estrogen receptor does not stimulate IP production $\text{in}$$\text{vitro}$. These findings represent the first report of an estrogenic effect of o,p'-DDT in a completely $\text{in}$$\text{vitro}$ system.     

Dopamine agonists reverse the elevated 3H-neuroleptic binding in neuroleptic-pretreated rats.

Chronic administration of large doses of haloperidol (10 mg/kg/day for 21 days) resulted in a 37–45% increase in the specific binding of ³H-spiperone and a 28% increase in the specific binding of ³H-apomorphine in rat striatal homogenates. The increase in ³H-spiperone binding in neuroleptic-pretreated rats could be reversed significantly by a five day administration of either bromocryptine (35 mg/kg p.o.) or L-DOPA (200 mg/kg p.o.)+ Carbidopa (20 mg/kg p.o.). Treatment of normal rats for 5 days with either L-DOPA or bromocryptine alone had no effect on ³H-spiperone binding.These results indicate that dopamine agonists can reverse the neuroleptic-induced elevation of brain neuroleptic binding, suggesting that short-term high-dose therapy with dopamine agonists might be of some value in alleviating neuroleptic-induced tardive dyskinesia clinically.     

The prophylactic action of (−)-Epicatechin against alloxan induced diabetes in rats

(?)-Epicatechin (1) was isolated from the bark of an Indian medicinal plant $\text{Pterocarpus}$$\text{marsupium}$ Roxb. the water extract of which is used as an antidiabetic drug (2). (?)-Epicatechin administration to albino rats of either sex in doses of 30 mg/kg (i.p.) for two days prior to alloxan (150 mg/kg i.p.) administration, and continued for next 24 hours was able to protect the animals against the diabetogenic actions of alloxan. The protection by (?)-epicatechin may be due to scavenging of the deleterious and highly reactive hydroxyl radical which is generated by alloxan.     

Synchronized breeding in cattle using PGF2α and LHRH/FSHRH stimulatory analogs

Two studies were conducted to synchronize breeding in cattle using PGF₂α and LHRH/FSHRH analogs. In the first study, 60 mature lactating Angus cows were assigned at random to 4 treatment groups: saline and saline (SS); 30 mg PGF₂α tham salt + saline (PS); saline + 2 mg D-ala⁶-des-GlyNH₂¹⁰ LHRH/FSHRH ethylamide (D-ala⁶) (SA); 30 mg PGF₂α tham salt + 2 mg D-ala⁶ (PA). The first letter of the two-letter code for each group always indicates a dual injection at an 11-day interval. PGF₂α or saline was administered intramuscular (im) twice at an 11 day interval. D-ala⁶ or saline was administered 48 hr after PGF₂α treatment. In the SA group, the D-ala⁶ was administered at first signs of estrus, and cows were then artificially inseminated (AI) 24 hr later. All cows in the PS group were inseminated 72 hr after the second PGF₂α injection. In the SS group, cows were inseminated 24 hr after first signs of estrus. An additional 6 mature lactating Angus cows were added equally to the PS and PA groups to evaluate changes in serum LH. The percent calf crops was: SS = 40% (frsol|6/15); PS = 47% ($\text{7}\text{15}$); SA = 47% ($\text{7}\text{15}$); PA = 53% ($\text{8}\text{15}$). In the second study, 51 mature lactating Angus cows and 39 Holstein heifers were assigned at random to 3 treatment groups: saline + saline (SS); 33.4 mg PGF₂α tham salt + saline (PS); 33.4 mg PGF₂α tham salt + 1 mg D-leu⁶-des GlyNH₂¹⁰ LHRH/FSHRH ethylamide (D-leu⁶) (PL). PGF₂α tham salt or saline was administered im twice at an 11 day interval. D-leu⁶ or saline was administered 68 hr following the second PGF₂α treatment. Cows pretreated with PGF₂α were inseminated 80 hr after the second PGF₂α injection. In the SS group, cows were administered saline at the time of natural estrus and were artificially inseminated 12 hr later. Calving percent to the first AI was SS = 70% ($\text{21}\text{30}$); PS = 53% ($\text{16}\text{30}$) and PL = 40% ($\text{12}\text{30}$). An additional 10 mature lactating Angus cows were used to evaluate changes in serum LH. Five of the cows were assigned to the PS treatment and five to the PL treatment. Sequential blood samples were collected to monitor serum LH levels. Using the Chi-square test, there were no significant differences between calving percentages of the control and PGF₂α treated cows in either study. These results indicate that the PGF₂α treatments were successful in timed artificial insemination of cows without detection of estrus. The LHRH/FSHRH analogs did not improve the conception even though they appear to induce a pituitary release of LH simultaneously in all cows within 1 hr of treatment.     

Avermectin B1a: an irreversible activator of the gamma-aminobutyric acid-benzodiazepine-chloride-ionophore receptor complex

Avermectin B_1a, an antihelminthic macrocyclic lactone, has been previously shown to reduce muscle membrane resistance by stimulating γ-aminobutyric acid-mediated chloride conductance. Since the benzodiazepine receptor is coupled to a receptor for γ-aminobutyric acid and related chloride ionophore, the effects of Avermectin B_1a on [³H]diazepam binding to the benzodiazepine receptor were studied. In well-washed membrane fragments from rat cerebral cortex, Avermectin B_1a markedly increased the binding of [³H]diazepam to benzodiazepine receptors. This effect was qualitatively similar to that observed with either γ-aminobutyric acid or chloride ion and was partially reversed by the γ-aminobutyric acid receptor antagonist, bicuculline. In contrast to the effects of γ-aminobutyric acid and chloride, the enhanced binding of [³H]benzodiazepine elicited by Avermectin B_1a was $\text{not}$ reversed by extensive washing of the membrane preparation. Avermectin B_1a appears to irreversibly modify benzodiazepine receptors at a γ-aminobutyric acid-chloride recognition site and may be valuable in biochemical studies of the regulation of benzodiazepine receptor function.     

Benzodiazepine receptor: Heterogeneity in rabbit brain

Binding characteristics of benzodiazepine receptors were studied with synaptosomal and microsomal membranes from rabbit brain $\text{in}$$\text{vitro}$ utilizing [methyl-³H]diazepam. In synaptosomal membranes, both high and low affinity binding sites were identified with the dissociation constants (K_d) of 4.92 nM and 83.8 nM, respectively. However, only the high affinity site was identified with K_d of 3.96 nM with microsomal membranes. Benzodiazepine binding sites appear to include at least two subpopulations of receptors, one with high affinity and another with low affinity binding site.     

In vitro and in vivo inhibition by zopiclone of benzodiazepine binding to rodent brain receptors.

Up to now the only drugs known to be able to inhibit the binding of benzodiazepines to rodent brain receptors are members of this chemical family.Zopiclone (RP 27 267), a new drug with a pharmacological profile similar to that of chlordiazepoxide and nitrazepam but entirely different chemically from benzodiazepines, has been tested for its ability to inhibit benzodiazepine binding. $\text{In vitro}$ and $\text{in vivo}$ studies have shown that zopiclone is able to inhibit the binding of [³H] diazepam and [³H] flunitrazepam to brain receptors. The potency of zopiclone is quite comparable to that of diazepam and nitrazepam $\text{in vitro}$ and to that of chlordiazepoxide $\text{in vivo}$.These results confirm the pharmacological similarities existing between zopiclone and the benzodiazepines.     

Effects of oral clonidine on plasma 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) in man: Preliminary report

Repeated (N=15) administration of clonidine (0,1,5 μg/kg,p.o.) to three normotensive male subjects resulted in significant decreases in plasma free 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) at three hours for both the 1 μg/kg dose (p < .05) and the 5 μg/kg dose (p < .01) when compared to concentrations following placebo. The mean decrement in plasma free MHPG following a 5 μg/kg dose was 36%. Systolic blood pressure fell a mean of 17 mmHg after 1 μg/kg and 37 mmHg after 5 μg/kg of clonidine. The application of a clonidine challenge test to assess noradrenergic receptor sensitivity $\text{in}$$\text{vivo}$ is discussed.